05:24 PM EST, 02/13/2025 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said its Phase 3 trial evaluating opdualag for the adjuvant treatment of patients with completely resected stage III-IV melanoma did not meet its primary endpoint of recurrence-free survival.

The safety profile observed in the trial was consistent with the known profiles of nivolumab and relatlimab, the company stated.

"We are disappointed" by the trial's outcome, Jeffrey Walch, opdualag's global program lead, Bristol-Myers Squibb ( BMY ), said. "Patients whose tumors are completely resected before treatment may not have sufficient antitumor T cells in place for opdualag to have its maximal effect."

Despite the trial outcome, Walch said opdualag remains a standard of care in the first-line treatment of unresectable or metastatic melanoma. The company continues to evaluate opdualag in other tumor types, including non-small cell lung cancer.